Comparison between standard heparin and tinzaparin for haemodialysis catheter lock

ASAIO Journal

Volumn 56, Issue 1, 2010, Pages 42-47

  Malo, Josianne ^a   Jolicoeur, Carine ^b   Theriault, Fannie ^b   Lachaine, Jean ^c   Senecal, Lynne ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-COAGULATION; END STAGE RENAL DISEASE; HAEMODIALYSIS; HEMODIALYSIS CATHETER; KAPLAN-MEIER; SURVIVAL ANALYSIS; THROMBOLYTIC; UNFRACTIONATED HEPARINS;

DIALYSIS; HEMODIALYZERS; LOCKS (FASTENERS); POLYSACCHARIDES; WIND TUNNELS;

CATHETERS;

FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

AGED; CATHETERIZATION, CENTRAL VENOUS; CROSS-OVER STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; RENAL DIALYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 76849104098     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3181c84e61     Document Type: Article

References (18)

1. Lord H, Jean N, Dumont M, et al: Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 22: 58-66, 2002.
2. Bramham K, Varrier M, Asgari E, Makanjuola D: Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: Equal safety, efficacy and economical parity. Nephron Clin Pract 110: c107-c113, 2008.
3. Davenport A: Anticoagulation options for intermittent haemodialysis. Minerva Urol Nefrol 58: 171-180, 2006.
4. Hainer JW, Sherrard DJ, Swan SK, et al: Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 40: 531-538, 2002.
5. Barrett JS, Gibiansky E, Hull RD, et al: Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 39: 431-446, 2001.
6. Nagge J, Crowther M, Hirsh J: Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162: 2605-2609, 2002.
7. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V: Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 25: 725-733, 2002.
8. Section V: Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 17 (suppl 7): 63-71, 2002.
9. Canaud B, My H, Morena M, et al: Dialock: A new vascular access device for extracorporeal renal replacement therapy. Preliminary clinical results. Nephrol Dial Transplant 14: 692-698, 1999.
10. Canaud B, Morena M, Leray-Moragues H: [Dialock: Results of a French multicenter study.] Nephrologie 22: 391-397, 2001.
11. Naumnik B, Borawski J, Mysliwiec M: Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: A prospective study. Nephrol Dial Transplant 18: 1376-1382, 2003.
12. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S-203S, 2004. (Pubitemid 39297954)
13. Polkinghorne KR, McMahon LP, Becker GJ: Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40: 990-995, 2002.
14. Brophy DF, Martin EJ, Gehr TW, Carr ME, Jr: Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 44: 270-277, 2004.
15. Moran JE, Ash SR: Locking solutions for hemodialysis catheters; heparin and citrate-a position paper by ASDIN. Semin Dial 21: 490-492, 2008.
16. Holley JL, Bailey S: Catheter lock heparin concentration: Effects on tissue plasminogen activator use in tunneled cuffed catheters. Hemodial Int 11: 96-98, 2007.
17. Agharazii M, Plamondon I, Lebel M, et al: Estimation of heparin leak into the systemic circulation after central venous catheter heparin lock. Nephrol Dial Transplant 20: 1238-1240, 2005.
18. Geerts WH, Pineo GF, Heit JA, et al: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 338S-400S, 2004.